E!10082, rosaGBS, ProNoxis

Reference number 2016-01010
Coordinator PRONOXIS AB
Funding from Vinnova SEK 3 732 312
Project duration April 2016 - March 2019
Status Ongoing
Venture Eurostars

Purpose and goal

We will develop and improve our development of new therapies and immunological understanding of the role of reactive oxygen species (ROS) in severe autoimmunity. We hope that the result of this project will be a base for industrial partnership to advance a new therapy for severe and life threatening autoimmune diseases into clinical validation The Project aims at combining expertise in radical oxygen species (ROS) regulation of autoimmunity with methods for medicinal chemistry and neurotoxicity. This synergistic collaboration will be implemented in validation of new potential drugs for treatment of autoimmunity and increase the knowledge of ROS/immunology by focusing on NADPH oxidases (NOX) activating drugs and at validating them in preclinical cell systems of NOX, animals models of autoimmunity and translational efficacy and safety models of neurotoxicity. The project addresses an immunological mechanism that needs external expertise for further development of treatment of the rare autoimmune disease GBS with unique molecules developed by ProNoxis. The project will bring new drug candidates for GBS using a new immunological mechanism and also create new commercial service opportunities for NEURIX and REDGLEAD in drug delivery and safety.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.